Compounds, compositions and methods for isolating nucleic acids
By using a composition covalently linked to the linker at low pH conditions to capture and release nucleic acids under high pH conditions, the time-consuming and incompatibility problems of isolating nucleic acids in the prior art is solved, and rapid and efficient nucleic acids are achieved Compatibility between separation and subsequent applications.
Patent Information
- Application Number
- CN202380035234.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-22
- Filing Date
- 2023-04-21
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art has time-consuming and incompatible components in the isolation of nucleic acids from samples, such as chaotropic reagents, salts, surfactants and organic solvents, which affect the rapid and efficient separation of nucleic acids and subsequent analysis.
Using a composition containing a solid surface, a linker covalently connected to the solid surface and a specific portion, nucleic acid separation methods suitable for rapid separation and downstream applications by capturing nucleic acids at low pH conditions and rapidly releasing at higher pH conditions. .
It is possible to efficiently isolate nucleic acids in a short time (less than 10 minutes), and the released nucleic acids can be directly used in downstream applications such as PCR reactions without further processing, avoiding interference of components that are incompatible with downstream applications.
Smart Images

Figure CN119095959A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 333,813, filed on April 22, 2022, the entirety of which is incorporated herein by reference. Technical Field
[0003] Provided herein are compounds, compositions, and methods for rapidly isolating nucleic acids from a sample. Background Art
[0004] Isolation of nucleic acids from samples is a critical step in many biochemical and diagnostic procedures, such as those that rely on nucleic acid amplification or sequencing reactions. Although compositions and methods for isolating nucleic acids from samples exist, many compositions and methods are time consuming and / or involve the use of components that are incompatible with downstream applications (e.g., sequencing reactions), such as chaotropic agents, salts, surfactants, and organic solvents. Summary of the invention
[0005] In one aspect, disclosed herein is a composition comprising:
[0006] Solid surface;
[0007] a linker covalently attached to a solid surface; and
[0008] The moiety of formula (I) covalently linked to the linker:
[0009]
[0010] in:
[0011] X is selected from O, S, S(O) and S(O)2;
[0012] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano, nitro, -OR a 、-SR b 、-C(O)OR c 、-C(O)NR d R e 、-OC(O)NR f R g 、-NRh C(O)NR i R j and-NR h C(S)NR i R j , where each R a , R b , R c , R d , R e , R f , R g , R h , R i and R j Independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl and aryl.
[0013] In some embodiments, the solid surface comprises a material selected from silica, glass, a polymer, and a metal. In some embodiments, the solid surface comprises a polymer selected from cellulose, cellulose acetate, nitrocellulose, nylon, polyester, polyethylene, polyethersulfone, polyolefin, polyvinylidene fluoride, polyacrylate, polystyrene, or any combination thereof. In some embodiments, the solid surface is in the form of beads, resins, magnetic particles, membranes, vials, plates, films, tubes, syringes, columns, boxes, pipette tips, microfluidic columns, or test tubes.
[0014] In some embodiments, the linker comprises one or more methylene, ether, ester, amide, carbamate, carbonate, urea, thioether, thioester, thioamide, thiocarbamate, thiocarbonate, thiourea, arylene, heteroarylene or heterocyclyl moieties or any combination thereof. In some embodiments, the linker comprises one or more -CH2-, -O-, -C(O)O-, -C(O)NH-, -NHC(O)O-, -OC(O)O-, -NHC(O)NH-, -S-, -C(O)S-, -C(S)NH-, -NHC(S)O-, -OC(S)O-, -NHC(S)NH-, arylene, heteroarylene or heterocyclyl moieties or any combination thereof.
[0015] In some embodiments, the linker comprises a moiety selected from:
[0016]
[0017] In some embodiments, the linker has the following structure:
[0018] -(CH2) n1 -Z-(CH2) n2 -
[0019] wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8, and Z is selected from -NHC(O)NH-, -C(O)NH-, -OC(O)NH-, -OC(O)O-, -NHC(O)S-, -NHC(S)NH-, -O-, -C(O)O- and a bond.
[0020] In some embodiments, the linker is selected from:
[0021]
[0022]
[0023] In some embodiments, the linker has the following structure:
[0024]
[0025] In some embodiments, X is O. In some embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is hydrogen.
[0026] In some embodiments, the solid surface further comprises one or more additional moieties covalently bound to the surface. In some embodiments, the solid surface further comprises at least one polyethylene glycol (PEG) moiety covalently bound to the surface.
[0027] In another aspect, disclosed herein is a method of isolating nucleic acid from a sample, the method comprising:
[0028] (a) providing a sample containing nucleic acid;
[0029] (b) contacting the sample with a composition disclosed herein (e.g., a composition disclosed herein, e.g., a composition comprising: a solid surface; a linker covalently attached to the solid surface; and a moiety of formula (I) covalently attached to the linker) at a pH of less than about 8.0, wherein nucleic acids bind to the composition to provide a nucleic acid binding composition; and
[0030] (c) isolating the nucleic acid binding composition from the sample.
[0031] In some embodiments, step (b) is performed at a pH of about 2.0 to less than about 8.0. In some embodiments, step (b) is performed at a pH of about 6.0 to about 7.5. In some embodiments, step (b) includes contacting the sample with the composition for about 10 seconds to about 10 minutes. In some embodiments, step (b) includes contacting the sample with the composition for about 1 minute to about 5 minutes.
[0032] In some embodiments, the method further comprises one or more steps of washing the nucleic acid binding composition after step (c) by contacting the composition with a wash solution having a pH of less than about 8.0.
[0033] In some embodiments, the method further comprises a step of contacting the nucleic acid binding composition with an elution solution at a pH of about 8.5 or higher to release nucleic acids from the composition. In some embodiments, the elution solution comprises an aqueous buffer. In some embodiments, the method further comprises contacting the nucleic acid binding composition with an elution solution at a pH of about 8.5 to about 9.5. In some embodiments, the method further comprises contacting the nucleic acid binding composition with an elution solution at a pH of about 8.5 to about 9.0. In some embodiments, the method further comprises contacting the nucleic acid binding composition with the elution solution for about 10 seconds to about 10 minutes. In some embodiments, the method further comprises contacting the nucleic acid binding composition with the elution solution for about 1 minute to about 5 minutes.
[0034] In some embodiments, the method further comprises performing a polymerase chain reaction on the nucleic acid binding composition.
[0035] In some embodiments, the sample includes body fluid. In some embodiments, body fluid is selected from blood, saliva, lymph, milk, mucus, urine, sweat, amniotic fluid, cerebrospinal fluid, feces, vaginal secretions and semen. In some embodiments, the sample includes cultured cells, tissue cells or cells from body fluids (such as blood, saliva, lymph, milk, mucus, urine, sweat, amniotic fluid, cerebrospinal fluid, feces, vaginal secretions or semen). In some embodiments, the sample is a blood sample selected from whole blood, plasma and serum. In some embodiments, the sample is an environmental sample selected from soil and water. In some embodiments, the sample is a food sample (such as a meat sample). In some embodiments, the sample is a plant (such as a vegetable). In some embodiments, the sample includes viruses, bacteria, fungi (such as yeast or mold) or any combination thereof. In some embodiments, the sample includes a culture medium, a cell lysate, a cell supernatant or a purified part (such as a subcellular part) of a cell from a cultured cell.
[0036] In some embodiments, the method comprises the step of lysing the sample prior to step (b).
[0037] In some embodiments, nucleic acid is DNA. In some embodiments, DNA is selected from total DNA, mtDNA (mitochondrial DNA), gDNA (genomic DNA), cfDNA (cell-free DNA), ccfDNA (circulating cell-free DNA), cffDNA (cell-free fetal DNA), bacterial DNA, viral DNA and ctDNA (circulating tumor DNA). In some embodiments, nucleic acid is RNA. In some embodiments, RNA is selected from total RNA, miRNA, mRNA, tRNA, rRNA, siRNA, ctRNA (circulating tumor RNA) and viral RNA. In some embodiments, nucleic acid is total nucleic acid from sample.
[0038] In another aspect, disclosed herein is a compound of formula (IIa):
[0039]
[0040] or a salt thereof, wherein:
[0041] X is selected from O, S, S(O) and S(O)2;
[0042] L is the connector;
[0043] Each R a are independently selected from hydroxy, C1-C6 alkoxy and halo; and
[0044] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano, nitro, -OR a 、-SR b 、-C(O)OR c 、-C(O)NR d R e 、-OC(O)NR f R g NR h C(O)NR i R j and-NR h C(S)NR i R j , where each R a , R b , R c , Rd , R e , R f , R g , R h , R i and R j Independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl and aryl.
[0045] In some embodiments, X is O. In some embodiments, each R a is C1-C6 alkoxy. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is hydrogen.
[0046] In some embodiments, the linker comprises one or more methylene, ether, ester, amide, carbamate, carbonate, urea, thioether, thioester, thioamide, thiocarbamate, thiocarbonate, thiourea, arylene, heteroarylene or heterocyclyl moiety or any combination thereof. In some embodiments, the linker comprises one or more -CH2-, -O-, -C(O)O-, -C(O)NH-, -NHC(O)O-, -OC(O)O-, -NHC(O)NH-, -S-, -C(O)S-, -C(S)NH-, -NHC(S)O-, -OC(S)O-, -NHC(S)NH- or any combination thereof.
[0047] In some embodiments, L comprises a moiety selected from:
[0048]
[0049] In some embodiments, L has the formula:
[0050] -(CH2) n1 -Z-(CH2) n2 -
[0051] wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8, and Z is selected from -NHC(O)NH-, -C(O)NH-, -OC(O)NH-, -OC(O)O-, -NHC(O)S-, -NHC(S)NH-, -O-, -C(O)O- and a bond.
[0052] In some embodiments, L has a structure selected from the group consisting of:
[0053]
[0054] In some embodiments, L has the following structure:
[0055] BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 The structures of various amine-containing silane ligands are shown.
[0057] Figure 2 Shown is a reaction scheme for functionalizing magnetic silica beads using exemplary silane ligands.
[0058] Figure 3 Shown are the percent DNA binding and elution from various amine-functionalized magnetic silica particles, with binding at pH 6.5 and elution at pH 9.0.
[0059] Figure 4 Shown are the percent DNA binding and elution from various amine-functionalized magnetic silica particles, with binding at pH 7.4 and elution at pH 9.0.
[0060] Figure 5 Shown are the percent DNA binding and elution from morpholine functionalized magnetic silica particles at various binding pH values (5.8-8.4) and salt concentrations (0-600 mM NaCl), with elution at pH 9.0.
[0061] Figure 6 Shown are the percentage of DNA bound and eluted from morpholine-functionalized magnetic silica particles using various DNA input concentrations.
[0062] Figure 7 Shown are the percentages of RNA bound and eluted from morpholine-functionalized magnetic silica particles using various RNA input concentrations.
[0063] Figure 8 Isolation and concentration of ccfDNA (circulating cell-free DNA) using morpholino-functionalized beads is shown. DETAILED DESCRIPTION
[0064] Provided herein are compounds, compositions and methods for rapid separation of nucleic acids from samples. The compounds and compositions allow rapid capture of nucleic acids at low pH (e.g., less than about 8). When transitioning to a higher pH (e.g., about 8.5 or higher), nucleic acids can be rapidly released into solution. In some embodiments, the entire process can be carried out in less than 10 minutes, and nucleic acids can be released under conditions compatible with downstream applications (e.g., polymerase chain reaction (PCR), including reverse transcription PCR (RT-PCR)).
[0065] I. Definitions
[0066] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the embodiments described herein, some preferred methods, compositions, devices and materials are described herein. However, before describing the materials and methods of the present invention, it should be understood that the disclosure is not limited to specific molecules, compositions, methods or schemes as described herein, because these molecules, compositions, methods or schemes can be varied according to routine experiments and optimization. It should also be understood that the terms used in this specification are for the purpose of describing only specific forms or embodiments, and are not intended to limit the scope of the embodiments described herein.
[0067] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present disclosure should have the meanings commonly understood by those skilled in the art. For example, any terms and techniques used in conjunction with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those terms and techniques well known and commonly used in the art. The meaning and scope of the terms should be clear; however, if there is any potential ambiguity, the definitions provided herein take precedence over any dictionary or external definition. In addition, unless the context otherwise requires, singular terms should include plural terms, and plural terms should include singular terms.
[0068] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "peptide" refers to one or more peptides and equivalents thereof known to those skilled in the art, and so forth.
[0069] As used herein, the term "and / or" includes any and all combinations of the listed items, including any individual listed item. For example, "A, B, and / or C" includes A, B, C, AB, AC, BC, and ABC, each of which is considered to be described individually by the statement "A, B, and / or C".
[0070] As used herein, the term "comprising" and its language variants indicate the presence of the listed features, elements, method steps, etc., without excluding the presence of additional features, elements, method steps, etc. In contrast, the term "consisting of..." and its language variants indicate the presence of the listed features, elements, method steps, etc., and exclude any unlisted features, elements, method steps, etc., except for generally associated impurities. The phrase "consisting essentially of..." indicates the listed features, elements, method steps, etc., as well as any additional features, elements, method steps, etc. that do not substantially affect the basic properties of the composition, system, or method. Many embodiments herein are described using open "comprising" language. Such embodiments encompass multiple closed "consisting of..." and / or "consisting essentially of..." embodiments that may alternatively be stated or described using such language.
[0071] For the enumeration of numerical ranges herein, each intermediate value with the same degree of precision is expressly contemplated. For example, for the range of 6-9, in addition to 6 and 9, the numbers 7 and 8 are also contemplated, and for the range of 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0 are expressly contemplated.
[0072] Definitions of specific functional groups and chemical terms are described in more detail below. For purposes of this disclosure, the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, vol. 75 The chemical elements are identified by reference to the inside cover of the 19th century, and specific functional groups are generally defined as described therein. In addition, the following references describe the general principles of organic chemistry as well as specific functional moieties and reactivities: Sorrell, Organic Chemistry, vol. 2 Edition, University Science Books, Sausalito, 2006; Smith, March's Advanced Organic Chemistry: Reactions, Mechanism, and Structure, pp. 7 Edition, John Wiley & Sons, Inc., New York, 2013; Larock, Comprehensive Organic Transformations, Vol. 3ed., John Wiley & Sons, Inc., New York, 2018; and Carruthers, Some Modern Methods of Organic Synthesis, pp. 3 ed., Cambridge University Press, Cambridge, 1987; the entire contents of each of which are incorporated herein by reference.
[0073] As used herein, the term "alkyl" refers to a straight or branched saturated hydrocarbon chain. The alkyl chain may include, for example, 1 to 30 carbon atoms (C1-C 30 alkyl), 1 to 24 carbon atoms (C1-C 24 Alkyl), for example, 1 to 16 carbon atoms (C1-C 16 alkyl), 1 to 14 carbon atoms (C1-C 14 alkyl), 1 to 12 carbon atoms (C1-C 12 alkyl), 1 to 10 carbon atoms (C1-C 10 The alkyl group may be a C1-C8 alkyl group, a C1-C6 alkyl group, a C1-C6 alkyl group, a C1-C6 alkyl group, or a C1-C4 alkyl group. Representative examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl.
[0074] As used herein, the term "alkenyl" refers to a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond. The double bond can be located at any position within the hydrocarbon chain. Representative examples of alkenyl include, but are not limited to, vinyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.
[0075] As used herein, the term "alkynyl" refers to a straight or branched hydrocarbon chain containing at least one carbon-carbon triple bond. The triple bond can be located at any position within the hydrocarbon chain. Representative examples of alkynyl include, but are not limited to, ethynyl, propynyl, and butynyl.
[0076] As used herein, the term "aryl" refers to an aromatic carbocyclic ring system having a single ring (monocyclic) or multiple rings (bicyclic or tricyclic) and zero heteroatoms, including fused ring systems. As used herein, aryl contains 6-20 carbon atoms (C6-C 20 aryl), 6 to 14 ring carbon atoms (C6-C 14 aryl), 6 to 12 ring carbon atoms (C6-C12 aryl) or 6 to 10 ring carbon atoms (C6-C 10 Representative examples of aryl include, but are not limited to, phenyl, naphthyl, anthracenyl, and phenanthrenyl.
[0077] As used herein, the term "cyano" refers to the group -CN.
[0078] As used herein, the term "cycloalkyl" refers to a saturated carbocyclic ring system containing three to ten carbon atoms and zero heteroatoms. The cycloalkyl can be monocyclic, bicyclic, bridged, fused or spirocyclic. Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl and bicyclo[5.2.0]nonyl.
[0079] As used herein, the term "halogen" or "halo" means F, Cl, Br or I.
[0080] As used herein, the term "haloalkyl" refers to an alkyl as defined herein, wherein at least one hydrogen atom (e.g., one, two, three, four, five, six, seven, or eight hydrogen atoms) is replaced by halogen. In some embodiments, each hydrogen atom of the alkyl is replaced by halogen. Representative examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, and 3,3,3-trifluoropropyl.
[0081] As used herein, the term "heteroaryl" refers to an aromatic group having a single ring (monocyclic) or multiple rings (bicyclic or tricyclic) of one or more ring heteroatoms independently selected from O, N and S. An aromatic monocyclic ring is a five-membered or six-membered ring containing at least one heteroatom independently selected from O, N and S (e.g., 1, 2, 3 or 4 heteroatoms independently selected from O, N and S). A five-membered aromatic monocyclic ring has two double bonds, and a six-membered aromatic monocyclic ring has three double bonds. An example of a bicyclic heteroaryl is a monocyclic heteroaryl ring fused to a monocyclic aryl as defined herein or a monocyclic heteroaryl as defined herein. An example of a tricyclic heteroaryl is a monocyclic heteroaryl ring fused to two rings independently selected from a monocyclic aryl as defined herein or a monocyclic heteroaryl as defined herein. Representative examples of monocyclic heteroaryl groups include, but are not limited to, pyridinyl (including pyridin-2-yl, pyridin-3-yl, pyridin-4-yl), pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, benzopyrazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, imidazolyl, thiazolyl, isothiazolyl, thienyl, furanyl, oxazolyl, isoxazolyl, 1,2,4-triazinyl, and 1,3,5-triazinyl. Representative examples of bicyclic heteroaryl include but are not limited to benzimidazolyl, benzodioxolyl, benzofuranyl, benzoxadiazolyl, benzopyrazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxadiazolyl, benzoxazolyl, chromenyl, imidazopyridine, imidazothiazolyl, indazolyl, indolyl, isobenzofuranyl, isoindolyl, isoquinolyl, naphthyridinyl, purinyl, pyridoimidazolyl, quinazolinyl, quinolyl, quinoxalinyl, thiazolopyridyl, thiazolopyridyl, thiazolopyrimidinyl, thienopyrrolyl and thienothienyl. Representative examples of tricyclic heteroaryl include but are not limited to dibenzofuranyl and dibenzothienyl. Monocyclic, bicyclic and tricyclic heteroaryl are connected to the parent molecular moiety by any carbon atom or any nitrogen atom contained in the ring.
[0082] As used herein, the term "heterocycle" or "heterocyclic" refers to a saturated or partially unsaturated non-aromatic cyclic group having one or more ring heteroatoms independently selected from O, N and S. It means a monocyclic heterocycle, a bicyclic heterocycle or a tricyclic heterocycle. A monocyclic heterocycle is a three-, four-, five-, six-, seven- or eight-membered ring containing at least one heteroatom independently selected from O, N and S. A three- or four-membered ring contains zero or one double bond and one heteroatom selected from O, N and S. A five-membered ring contains zero or one double bond and one, two or three heteroatoms selected from O, N and S. A six-membered ring contains zero, one or two double bonds and one, two or three heteroatoms selected from O, N and S. Seven- and eight-membered rings contain zero, one, two or three double bonds and one, two or three heteroatoms selected from O, N and S. Representative examples of monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinyl, oxazolidinyl, oxadiazolyl, oxazolidin ... , oxetanyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, 1,2-thiazinyl, 1,3-thiazinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl (thiomorpholine sulfone), thiopyranyl and trithianyl. The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a spiroheterocyclic group, or a bridged monocyclic heterocycle system in which two non-adjacent atoms of the ring are connected by an alkylene bridge of 1, 2, 3 or 4 carbon atoms or an alkenylene bridge of two, three or four carbon atoms. Representative examples of bicyclic heterocycles include, but are not limited to, benzopyranyl, benzothiopyranyl, chromanyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, 2,3-dihydroisoquinolinyl, 2-azaspiro[3.3]heptan-2-yl, azabicyclo[2.2.1]heptyl (including 2-azabicyclo[2.2.1]hept-2-yl), 2,3-dihydro-1H-indolyl, isoindolinyl, octahydrocyclopenta[c]pyrrolyl, octahydropyrrolopyridinyl, and tetrahydroisoquinolinyl. Examples of tricyclic heterocycles are bicyclic heterocycles fused to phenyl, or bicyclic heterocycles fused to monocyclic cycloalkyl, or bicyclic heterocycles fused to monocyclic cycloalkenyl, or bicyclic heterocycles fused to monocyclic heterocycles, or bicyclic heterocycles wherein two non-adjacent atoms of the bicyclic ring are linked by an alkylene bridge of 1, 2, 3 or 4 carbon atoms or an alkenylene bridge of 2, 3 or 4 carbon atoms.Examples of tricyclic heterocycles include, but are not limited to, octahydro-2,5-epoxypentadiene, hexahydro-2H-2,5-methanocyclopenta[b]furan, hexahydro-1H-1,4-methanocyclopenta[c]furan, aza-adamantane (1-azatricyclo[3.3.1.1. 3,7 ]decane) and oxa-adamantane (2-oxatricyclo[3.3.1.1 3,7 The monocyclic, bicyclic, and tricyclic heterocycles are attached to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the rings.
[0083] As used herein, the term "nitro" refers to the group -NO2.
[0084] As used herein, the term "sample" is used in its broadest sense. In a sense, it is intended to include specimens or cultures obtained from any source, as well as biological samples and environmental samples. Biological samples can be obtained from animals (including humans) and cover fluids, solids, tissues and gases. Biological samples include blood products, such as blood plasma, serum, etc. Samples can also refer to cells or cell lysates. Cell lysates can include cells or lysates that have been cracked with a lysing agent, such as rabbit reticulocytes or wheat germ lysates. Environmental samples include environmental materials, such as surface materials, soil, water (such as wastewater), crystals and industrial samples. Samples can also include purified samples, such as purified protein samples. However, such examples should not be construed as limiting the sample types applicable to the present disclosure.
[0085] When a group or moiety can be substituted, the term "substituted" indicates that one or more (e.g., 1, 2, 3, 4, 5, or 6; in some embodiments, 1, 2, or 3; and in other embodiments, 1 or 2) hydrogen atoms on the group indicated in the expression using "substituted" can be replaced by a list of the indicated groups or by suitable substituents known to those skilled in the art (e.g., one or more of the groups listed below), provided that the normal valence of the designated atom is not exceeded. Substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cycloalkyl, cycloalkenyl, guanidino, halo, haloalkyl, haloalkoxy, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazine, imino, oxo, nitro, phosphate, phosphonate, sulfonic acid, thiol, thione, or a combination thereof.
[0086] As used herein, in chemical structures, indicates:
[0087]
[0088] It indicates the point of attachment of one moiety to another, such as a substituent to the rest of a compound.
[0089] For the compounds described herein, radicals and substituents may be chosen based on the allowed valences of atoms and substituents such that selection and substitution results in stable compounds, e.g., compounds that do not spontaneously undergo transformations such as by rearrangement, cyclization, elimination, and the like.
[0090] When substituents are specified by their conventional chemical formula written from left to right, they optionally encompass substituents resulting from writing the structure from right to left, for example -CH2O- optionally also enumerates -OCH2-, and -OC(O)NH- optionally also enumerates -NHC(O)O-.
[0091] II. Compositions and Compounds
[0092] Provided herein are compounds and compositions that can be used to rapidly separate nucleic acids from samples. The compounds and compositions include morpholino moieties or derivatives thereof. At relatively low pH (e.g., less than about 8), the morpholino moieties are protonated and positively charged, so that negatively charged nucleic acids can be rapidly bound. When converted to a higher pH (e.g., about 8.5 or higher), the morpholino moieties are deprotonated, so that nucleic acids are rapidly released into the solution. The disclosed compositions include morpholino moieties or derivatives thereof (e.g., morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide or its salt) connected to a solid surface by a joint. Although similar materials with other ligands (e.g., imidazole, methylpiperazine and other primary and secondary amines) can also bind nucleic acids, compositions including morpholino groups (or derivatives thereof) can rapidly release a large amount of nucleic acids (e.g., in some embodiments, at least 80% of the bound nucleic acids can be released in less than 5 minutes or less than 1 minute). This provides significant advantages for the disclosed materials. In addition, nucleic acids can be released using elution solutions that do not require components (e.g., chaotropes) that would disrupt downstream applications (e.g., sequencing reactions). Therefore, disclosed compounds and compositions can be used to quickly and effectively separate nucleic acids to provide solutions that can be directly used in downstream applications without the need for further sample processing.
[0093] Thus, disclosed herein are compositions comprising: a solid surface; a linker covalently attached to the solid surface; and a moiety of formula (I) covalently attached to the linker:
[0094]
[0095] in:
[0096] X is selected from O, S, S(O) and S(O)2;
[0097] R 1 , R 2 , R 3, R 4 , R 5 , R 6 , R 7 and R 8 Each is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano, nitro, -OR a 、-SR b 、-C(O)OR c 、-C(O)NR d R e 、-OC(O)NR f R g NR h C(O)NR i R j and-NR h C(S)NR i R j , where each R a , R b , R c , R d , R e , R f , R g , R h , R i and R j Independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl and aryl.
[0098] In the moiety of formula (I), X is selected from O, S, S(O) and S(O)2. In some embodiments, X is O. In some embodiments, X is S. In some embodiments, X is S(O). In some embodiments, X is S(O)2.
[0099] In the formula (I), R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano, nitro, -OR a 、-SR b 、-C(O)OR c 、-C(O)NR d Re 、-OC(O)NR f R g NR h C(O)NR i R j and-NR h C(S)NR i R j , where each R a , R b , R c , R d , R e , R f , R g , R h , R i and R j R is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl and aryl. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is independently selected from hydrogen, C1-C3 alkyl, halo and -OR a , where R a is selected from hydrogen and C1-C3 alkyl. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 One or two of them are independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, heterocyclic, halo, cyano, nitro, -OR a 、-SR b 、-C(O)OR c 、-C(O)NR d R e 、-OC(O)NR f R g 、-NR h C(O)NR i R j and-NR h C(S)NR i R j , and the remainder are hydrogen. In some embodiments, R1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 One or two of are independently selected from hydrogen, C1-C3 alkyl, halo and -OR a , where R a is selected from hydrogen and C1-C3 alkyl, and the remainder is hydrogen. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is hydrogen.
[0100] Any solid surface suitable for separating nucleic acids can be used. For example, in some embodiments, the solid surface comprises a material selected from silicon dioxide, glass, polymers and metals. In some embodiments, the solid surface is a glass surface. In some embodiments, the solid surface comprises silicon dioxide. In some embodiments, the solid surface comprises a polymer, such as a polymer selected from cellulose, cellulose acetate, nitrocellulose, nylon, polyester, polyethylene, polyethersulfone, polyolefin, polyvinylidene fluoride, polyacrylate, polystyrene or any combination thereof. The solid surface can be in the form of, for example, beads, resins, magnetic particles, films, vials, plates, films, tubes, syringes, columns, boxes, pipette tips, microfluidic columns or test tubes. In some embodiments, the solid surface is in the form of beads. In some embodiments, the solid surface is in the form of resins. In some embodiments, the solid surface is in the form of membranes. In some embodiments, the solid surface is in the form of plates. In some embodiments, the solid surface is in the form of pipette tips. In some embodiments, the solid surface is in the form of microfluidic columns.
[0101] In the composition, the moiety of formula (I) is connected to the solid surface via a linker. In some embodiments, the linker is a direct bond. In other embodiments, the linker separates the moiety of formula (I) from the solid surface by about about about about about about about about about about about about about about about or any suitable range therebetween (e.g., about about about In some embodiments, the linker separates the functional element from the rest of the compound of Formula (I) by about 1-200 atoms (e.g., about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 120, about 140, about 160, about 180, about 200, or any suitable range therebetween (e.g., about 2-20, about 10-50, etc.)).
[0102] The linker may include one or more groups independently selected from the following: methylene (-CH2-), ethylene (-CH=CH-), ethynyl (-C≡C-), ether (-O-), amine (-NR-, where R is hydrogen or alkyl), thioether (-S-), carbonyl (-C(O)-), thiocarbonyl (-C(S)-), sulfonyl (-S(O)2-), arylene, heteroarylene and heterocyclyl moieties or any combination thereof. For example, the above-mentioned moieties can be combined to form additional groups that can be included in the linker, for example, a carbonyl group and an ether group can together provide an ester moiety (-C(O)O-); a carbonyl group and two ether groups can together provide a carbonate moiety (-OC(O)O-); a carbonyl group and an unsubstituted amine group can together provide an unsubstituted amide moiety (-C(O)NH-); a carbonyl group and two unsubstituted amine groups can together provide an unsubstituted urea moiety (-NHC(O)NH-); a carbonyl group together with an unsubstituted amine group and an ester group can provide an unsubstituted carbamate moiety (-OC(O)NH-); a carbonyl group together with a thioether and an unsubstituted amine group can provide an S-thiocarbamate moiety; a thiocarbonyl group together with an ether and an unsubstituted amine group can provide an O-thiocarbamate moiety; multiple methylene groups can together form an alkylene chain, and the like.
[0103] In some embodiments, the linker comprises one or more methylene, ether, ester, amide, carbamate, carbonate, urea, thioether, thioester, thioamide, thiocarbamate, thiocarbonate, thiourea, arylene, heteroarylene or heterocyclyl moieties or any combination thereof. In some embodiments, the linker comprises one or more -CH2-, -O-, -C(O)O-, -C(O)NH-, -NHC(O)O-, -OC(O)O-, -NHC(O)NH-, -S-, -C(O)S-, -C(S)NH-, -NHC(S)O-, -OC(S)O-, -NHC(S)NH-, arylene, heteroarylene or heterocyclyl moieties or any combination thereof.
[0104] In some embodiments, the linker comprises one or more alkylene groups (e.g., -(CH2) n -, wherein n is 1-12, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, or any suitable range therebetween). In some embodiments, the linker comprises one or more branched alkylene groups.
[0105] In some embodiments, the linker has the formula -(CH2) n1 -Z-(CH2) n2 -, wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8, and Z is selected from -NHC(O)NH-, -C(O)NH-, -OC(O)NH-, -OC(O)O-, -NHC(O)S-, -NHC(S)NH-, -O-, -C(O)O- and a bond.
[0106] In some embodiments, the linker has the formula -(CH2) n1 -NH-C(O)-NH-(CH2) n2 -, wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8.
[0107] In some embodiments, the linker has a formula selected from:
[0108]
[0109] In some embodiments, the linker has the formula:
[0110]
[0111] In some embodiments, the linker can include one or more moieties produced by the reaction of two reactive groups (e.g., reactive groups known in various bioconjugation reactions). For example, the linker can include a triazole group formed by the reaction of an azide and an alkyne. Exemplary moieties that may be produced by such reactions include, but are not limited to:
[0112]
[0113] In some embodiments, in addition to the moiety of formula (I), the solid surface comprises one or more additional moieties. For example, the solid surface can be functionalized with additional ligands. In some embodiments, the solid surface further comprises one or more PEG ligands.
[0114] The composition can be prepared by reacting a solid surface with a compound comprising a moiety of formula (I). Typically, the compound comprising a moiety of formula (I) will have reactive groups complementary to reactive groups present on the solid surface to allow for covalent attachment. For example, a suitable solid surface can be reacted with a compound of formula (II):
[0115]
[0116] reaction, wherein RM is a reactive moiety, L is a linker, and X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 As defined and described herein. In some embodiments, the reactive moiety comprises a group selected from silanes, alkynes, azides, olefins, thiols, maleimides, amines, succinimide esters, -COOH groups, tetrazoles, aryl phosphines, and the like. For example, in some embodiments, RM comprises a moiety selected from:
[0117]
[0118] Each R a Independently selected from hydroxyl, C1-C6 alkoxy and halo (e.g., fluorine, chlorine or bromine). A skilled person will appreciate that when the compound of formula (II) includes any of the above groups, the solid surface will be functionalized with a complementary reactive group. For example, when the compound of formula (II) includes a group comprising an alkyne, the solid surface can be functionalized with an azide so that the compound of formula (II) can be attached to the solid surface via a click chemistry reaction (e.g., to form a triazole). Similarly, when the compound of formula (II) includes a succinimidyl ester group (i.e., ), the solid surface can be functionalized with a primary amine (-NH2) so that the compound of formula (II) can be linked to the solid surface via an amide bond.
[0119] In the compound of formula (II), the group L can be any suitable linking group. For example, in some embodiments, L includes one or more groups independently selected from the following: methylene (-CH2-), ethylene (-CH=CH-), ethynyl (-C≡C-), ether (-O-), amine (-NH-), thioether (-S-), carbonyl (-C(O)-), thiocarbonyl (-C(S)-), sulfonyl (-S(O)2-), arylene, heteroarylene and heterocyclyl moieties or any combination thereof. For example, the above moieties can be combined to form additional groups, such as esters, carbonates, amides, ureas, thioureas, carbamates, alkylenes, etc. In some embodiments, L includes one or more alkylenes (e.g., -(CH2) n -, wherein n is 1-12, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, or any suitable range therebetween). In some embodiments, L comprises one or more branched alkylene groups.
[0120] In some embodiments, L has the formula -(CH2) n1 -Z-(CH2) n2 -, wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8, and Z is selected from -NHC(O)NH-, -C(O)NH-, -OC(O)NH-, -OC(O)O-, -NHC(O)S-, -NHC(S)NH-, -O-, -C(O)O- and a bond.
[0121] In some embodiments, L has the formula -(CH2) n1 -NH-C(O)-NH-(CH2) n2 -, wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8.
[0122] In some embodiments, L has a formula selected from:
[0123]
[0124] In some embodiments, L has the formula:
[0125]
[0126] In some embodiments, provided herein is a compound of formula (IIa):
[0127]
[0128] Among them, L, X, R 1 , R 2 , R 3 , R 4 , R5 , R 6 , R 7 , R 8 and R a As defined and described herein.
[0129] In one embodiment, provided herein is a compound of the formula:
[0130]
[0131] III. How to use
[0132] The compositions disclosed herein can be used to quickly separate nucleic acids (e.g., DNA and RNA) from samples (e.g., biological samples). In one aspect, the present disclosure provides a method for separating nucleic acids from a sample, the method comprising:
[0133] (a) providing a sample containing nucleic acid;
[0134] (b) contacting the sample with a composition disclosed herein (e.g., a composition comprising: a solid surface; a linker covalently attached to the solid surface; and a moiety of formula (I) covalently attached to the linker) at a pH of less than about 8.0, wherein nucleic acids bind to the composition to provide a nucleic acid binding composition; and
[0135] (c) isolating the nucleic acid binding composition from the sample.
[0136] In some embodiments, the nucleic acid separated from the sample is selected from DNA and RNA. In some embodiments, the nucleic acid separated from the sample is DNA (e.g., genomic DNA (gDNA), plasmid DNA, cDNA, mitochondrial DNA (mtDNA), cosmid DNA, cell-free DNA (cfDNA), circulating cell-free DNA (ccfDNA), cell-free fetal DNA (cffDNA), bacterial DNA, viral DNA, circulating tumor DNA (ctDNA), total DNA, etc.). In some embodiments, the nucleic acid separated from the sample is RNA, such as messenger RNA (mRNA), microRNA (miRNA), pre-miRNA, ribosomal RNA (rRNA), mitochondrial RNA, non-coding RNA, circular RNA, small interfering RNA (siRNA), guide RNA, total RNA, etc. In some embodiments, the nucleic acid separated from the sample is total nucleic acid.
[0137] Any suitable sample containing nucleic acid can be used in the disclosed method.In some embodiments, sample includes body fluid, such as blood, saliva, lymph, milk, mucus, urine, sweat, amniotic fluid, cerebrospinal fluid, feces, vaginal secretions or semen.In some embodiments, sample includes cultured cells, tissue (such as fresh tissue or formalin fixed paraffin embedded (FFPE) tissue) or cells from body fluid.In some embodiments, sample includes virus, bacteria, fungus (such as yeast or mold) or any combination thereof.In some embodiments, sample is food sample, such as meat sample.In some embodiments, sample is plant, such as vegetable.In specific embodiments, sample is a blood sample selected from whole blood, blood plasma and serum.In some embodiments, sample is environmental sample, such as soil or water (such as wastewater).Described method can also be used for separating nucleic acid from other environments (such as agarose or polyacrylamide gel, or solution having been carried out target nucleic acid amplification).
[0138] In some embodiments, the method may also include a step of lysing the sample before contacting the sample with the composition disclosed herein. Any suitable method of lysing the sample may be used, including osmotic lysis (i.e., using a hypotonic solution), enzymatic lysis (e.g., using lysozyme), chemical lysis (e.g., using a detergent, such as a nonionic detergent or a cationic detergent, with or without other components, such as sodium hydroxide), physical lysis (e.g., by mechanical lysis, such as blending, shaking with glass beads, using a homogenizer or French press, using a sonicator, freeze-thaw cycles, or mechanical grinding) or thermal lysis or any combination thereof.
[0139] The method comprises a step of contacting a sample (e.g., a lysed sample) with a composition disclosed herein (e.g., a composition comprising a moiety of formula (I) as disclosed herein) such that nucleic acids in the sample bind to the composition to provide a nucleic acid binding composition. During this contacting step, the pH of the sample is less than about 8.0 to ensure that the moiety of formula (I) in the composition is positively charged. In some embodiments, the contacting step is performed at a pH of about 2.0 to about 8.0, about 2.5 to about 8.0, about 3.0 to about 8.0, about 3.5 to about 8.0, about 4.0 to about 8.0, about 4.5 to about 8.0, about 5.5 to about 8.0, or about 6.0 to about 7.5, e.g., about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0 , about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, or any range therebetween.
[0140] Nucleic acids rapidly bind to the compositions disclosed herein. For example, in some embodiments, greater than about 50% of the nucleic acids in a sample (e.g., greater than about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135 %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) is combined with the composition in less than about 10 minutes (e.g., less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 7 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes or less than about 1 minute). In some embodiments, greater than about 75% (e.g., greater than 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) of the nucleic acids in a sample are bound to the composition in less than about 10 minutes (e.g., less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 7 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, or less than about 1 minute). In some embodiments, greater than about 75% (e.g., greater than 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) of the nucleic acids in a sample are bound to the composition in less than about 5 minutes (e.g., less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, or less than about 1 minute). In some embodiments, greater than 75% (e.g., greater than 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) of the nucleic acids in a sample are bound to the composition in less than about 1 minute.Thus, although the step of contacting the sample with the composition can be performed for a longer period of time if convenient or desired, in some embodiments, the contacting step is performed for less than about 10 minutes (e.g., less than about 10 minutes, less than about 9 minutes, less than about 8 minutes, less than about 7 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, or less than about 1 minute), because this period of time is sufficient to bind the nucleic acid to the composition. In some embodiments, the contacting step is performed for about 10 seconds to about 10 minutes, or about 1 minute to about 5 minutes. The contacting step results in the generation of the nucleic acid binding composition.
[0141] The method optionally includes one or more washing steps after the contacting step. In some embodiments, the method also includes contacting at least one washing solution with the nucleic acid binding composition. Washing solution is typically an aqueous solution (such as aqueous buffer) optionally containing a chemical additive, such as a detergent, a salt (such as NaCl) or an organic solvent (such as methanol, ethanol, isopropanol, acetonitrile, DMSO or DMF), and the solution has a pH of about 2.0 to about 8.0, about 2.5 to about 8.0, about 3.0 to about 8.0, about 3.5 to about 8.0, about 4.0 to about 8.0, about 4.5 to about 8.0, about 5.5 to about 8.0 or about 6.0 to about 7.5, so that the composition will remain protonated, and nucleic acid will remain combined or aqueous, and other pollutants will be washed away. In some embodiments, the wash solution is an aqueous buffer solution having a pH of about 2.0 to about 8.0, about 2.5 to about 8.0, about 3.0 to about 8.0, about 3.5 to about 8.0, about 4.0 to about 8.0, about 4.5 to about 8.0, about 5.5 to about 8.0, or about 6.0 to about 7.5, e.g., about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0 .0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, or any range therebetween.
[0142] After the contacting step and the optional washing step, the nucleic acid binding composition can be used in a variety of different applications. In some embodiments, nucleic acids are released from the nucleic acid binding composition, for example, by contacting the nucleic acid binding composition with an elution solution having a pH of about 8.5 or higher (e.g., a pH of about 8.5 to about 9.5, such as about 8.5, about 8.6, about 8.7, about 8.8, about 8.9, about 9.0, about 9.1, about 9.2, about 9.3, about 9.4, about 9.4 or about 9.5, or any range therebetween). In some embodiments, the elution solution includes a buffer, such as tris (hydroxymethyl) aminomethane (Tris), 4- (2-hydroxyethyl) -1- piperazineethanesulfonic acid (HEPES), 3- (N- morpholino) propanesulfonic acid (MOPS), etc. The elution solution may include other components, such as salts, as long as those components are included in a concentration that does not interfere with downstream applications (e.g., PCR). For example, in some embodiments, the elution solution includes a salt (e.g., NaCl) having a concentration less than about 25 nM.
[0143] A significant advantage of the disclosed composition is that it releases nucleic acids at a very fast rate when transitioned to a higher pH. Although other compositions are capable of binding and releasing nucleic acids, including compositions similar to those described herein having moieties other than Formula (I) such as imidazole, methylpiperazine, amines such as primary amines (-NH2) or substituted amines such as -N(CH3)2 or -N(CH2CH2OH)2), the compositions disclosed herein can release large amounts of nucleic acids in a very short period of time. In some embodiments, contacting the nucleic acid binding composition with an elution solution having a pH of about 8.5 or higher results in a release of nucleic acids in less than about 5 minutes (e.g., less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, or less than about 1 minute). %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, In some embodiments, contacting the nucleic acid binding composition with an elution solution having a pH of about 8.5 or greater results in the release of greater than 75% of the bound nucleic acids (e.g., greater than 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) in less than about 5 minutes (e.g., less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, or less than about 1 minute). 7%, 98% or 99%). This greatly shortens the processing time required to separate nucleic acids from a sample. Thus, although the step of contacting the nucleic acid binding composition with the elution solution can be performed for a longer period of time if convenient or necessary, in some embodiments, the step is performed for less than about 5 minutes (e.g., less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, or less than about 1 minute), because this period of time is sufficient to effectively release the bound nucleic acids. In some embodiments, the step of contacting the nucleic acid binding composition with the elution solution is performed for about 10 seconds to about 10 minutes, or about 1 minute to about 5 minutes.
[0144] In embodiments where an elution solution is used, the elution solution does not contain a chaotropic agent (e.g., guanidine hydrochloride or guanidine isothiocyanate), an organic solvent (e.g., an alcohol (e.g., ethanol or methanol) or other organic solvents (e.g., dimethyl sulfoxide)), or a detergent (e.g., sodium dodecyl sulfate). Even trace amounts of such components in a target nucleic acid solution can severely limit the use of the nucleic acid in downstream processing or analysis. This is another significant advantage of the disclosed compositions - nucleic acids can be quickly released from the composition using an aqueous buffer that does not include components that would interfere with downstream applications.
[0145] When specific pH conditions are required in any of the method steps (eg, the contacting step, the optional washing step, and the elution step), the pH of the sample or solution can be adjusted to the indicated pH value using acidifying or basifying agents as required. Suitable acidulants include, but are not limited to, inorganic acids such as HCl, HBr, HClO4, HClO3, H2SO4, H2SO3, H3PO4, or H3PO3; organic acids such as 2-acetoxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthalenecarboxylic acid, isethionic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, benzenesulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, tetrafluoroboric acid, toluenesulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, and valeric acid. Suitable alkalizing agents include, but are not limited to, inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium bicarbonate, sodium carbonate, ammonia, diethanolamine, meglumine, lysine, arginine, ethanolamine, piperazine, tromethamine, triethanolamine, and the like.
[0146] In some embodiments, the nucleic acid binding composition can be used directly in downstream applications without an elution step. For example, in some embodiments, the nucleic acid binding composition can be used directly in an on-bead polymerase chain reaction.
[0147] In some embodiments, the isolated nucleic acid can be used in any number of downstream applications, such as methods for analyzing or further processing the nucleic acid. For example, in some embodiments, the disclosed methods further include steps for analyzing or processing the nucleic acid, such as using polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), quantitative PCR, quantitative reverse transcription PCR (RT-qPCR), real-time PCR, hot start PCR, single cell PCR, nested PCR, in situ colony PCR, digital PCR (dPCR), DropletDigitalPCR, or the like. TMPCR (ddPCR), emulsion PCR, ligase chain reaction (LCR), transcription-based amplification system (TAS), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), rolling circle amplification (RCA), hyperbranched RCA (HRCA), isothermal amplification, gel electrophoresis, capillary electrophoresis, mass spectrometry, fluorescence detection, UV spectroscopy, hybridization assay, DNA or RNA sequencing, reverse transcription, next generation sequencing (NGS), etc.
[0148] IV. Examples
[0149] Abbreviations used in the examples include the following: DCM is dichloromethane; DMF is dimethylformamide; MeOH is methanol; MS is mass spectrometry; NMR is nuclear magnetic resonance; RT is room temperature; and THF is tetrahydrofuran.
[0150] Example 1
[0151] Synthesis of 1-(3-morpholinopropyl)-3-(3-(triethoxysilyl)propyl)urea
[0152] 6.41 g of 3-morpholinopropylamine was added to 40 mL of anhydrous THF, and then 10 mL of 3-(triethoxysilyl)propyl isocyanate was slowly added. The solution was heated to reflux overnight. The solution was cooled to room temperature and purified by chromatography using a Teledyne ISCO system. The solvent system was DCM / MeOH, and the gradient was 0-20% MeOH in DCM. The compound was eluted at about 15% MeOH in DCM. The combined solution was rotary evaporated to remove the solvent, producing 9.5 g of a viscous colorless liquid (60% yield). MS: 392.6 (M+H); 1 H NMR (400MHz, methanol-d4) 3.88-3.79 (m, 6H), 3.70 (d, J = 5.1Hz, 4H), 3.17 (t, J = 7.0Hz, 2H), 3.10 (t, J = 7.0Hz, 2H), 2.48 (s, 4H), 2. 41(t,J=7.6Hz,2H), 1.69(p,J=7.2Hz,2H), 1.57(p,J=7.4Hz,2H), 1.22(td,J=7.1,2.1Hz,9H), 0.62(dd,J=9.8,6.9Hz,2H).
[0153] Example 2
[0154] Synthesis of Morpholine-functionalized Magnetic Silica Beads
[0155] Figure 2An overview of the synthesis procedure is provided in. 1 g of Grace MP-50 magnetic silica particles (6 μm) was added to 50 mL of toluene. The suspension was stirred at 200 rpm using an overhead mechanical stirrer. 1-(3-morpholinopropyl)-3-(3-(triethoxysilyl)propyl)urea (783 mg) was dissolved in 2 mL of DMF. The solution was added to the toluene suspension and stirred for 30 min at RT. The suspension was heated to 75°C overnight. The particles were washed three times with DMF and three times with water. The particles were stored in nanopure water. CHN elemental analysis: C (1.53%), H (0.40%), N (0.38%).
[0156] Example 3
[0157] Synthesis of functionalized magnetic silica beads
[0158] 1g Grace MP-50 magnetic silica particles (6μm) were added to 50mL toluene. The suspension was stirred at 200rpm using an overhead mechanical stirrer. 1-(3-morpholinopropyl)-3-(3-(triethoxysilyl)propyl)urea (783mg) was dissolved in 2mL DMF. The solution was added to the toluene suspension. 500μL acetic acid was added as an additive to improve the ligand coupling efficiency. The suspension was stirred at RT for 30min. The suspension was heated to 75°C overnight. The particles were washed three times with DMF and three times with water. The particles were stored in nanopure water. CHN elemental analysis: C (6.48%), H (1.2%), N (1.9%).
[0159] Additional magnetic silica beads were prepared according to a similar procedure using other amine-containing silane ligands in place of 1-(3-morpholinopropyl)-3-(3-(triethoxysilyl)propyl)urea (i.e., 1-(3-(1H-imidazol-1-yl)propyl)-3-(3-(triethoxysilyl)propyl)urea, 1-(3-(4-methylpiperazin-1-yl)propyl)-3-(3-(triethoxysilyl)propyl)urea, respectively). urea, 3-(trimethoxysilyl)propan-1-amine, 1-(3-(dimethylamino)propyl)-3-(3-(triethoxysilyl)propyl)urea, 2,2'-((3-(triethoxysilyl)propyl)azanediyl)bis(ethan-1-ol), and 1-(2-((2-(2-hydroxyethoxy)ethyl)(methyl)amino)ethyl)-3-(3-(triethoxysilyl)propyl)urea).
[0160] Example 4
[0161] DNA binding and elution assays
[0162] 1 mg of each amine-functionalized magnetic beads was added to 1 mL of 200 bp DNA solution (100 ng / mL, 10 mM PBS, pH 6.5). The suspension was mixed for 40 seconds. The particles were collected with a magnetic bar for 1 minute. The supernatant was collected to measure the remaining DNA concentration in the solution and thus calculate the binding percentage. dsDNA system (Promega) was used to quantify DNA concentration. 50 μL Tris buffer (10 mM, pH 9.0) was added to the magnetic particles, and the suspension was vortexed for 1 minute. The particles were collected with a magnetic bar. The elution solution was collected, and the DNA concentration in the elution solution was quantified to calculate the elution percentage.
[0163] Results are shown in Figure 3 Although all particles bound DNA rapidly, the morpholine-functionalized beads released much higher amounts of DNA than the other materials after a 1-minute elution step.
[0164] Example 5
[0165] DNA binding and elution assays
[0166] 1 mg of each amine-functionalized magnetic beads was added to 1 mL of 200 bp DNA solution (100 ng / ml, 10 mM PBS, pH 7.4). The suspension was mixed for 40 seconds. The particles were collected with a magnetic bar for 1 minute. The supernatant was collected to measure the remaining DNA concentration in the solution and thus calculate the binding percentage. dsDNA system (Promega) was used to quantify DNA concentration. 50 μL Tris buffer (10 mM, pH 9.0) was added to the magnetic particles, and the suspension was vortexed for 1 minute. The particles were collected with a magnetic bar. The elution solution was collected, and the DNA concentration in the elution solution was quantified to calculate the elution percentage.
[0167] Results are shown in Figure 4 Although all particles bound DNA rapidly, the morpholine-functionalized beads released much higher amounts of DNA than the other materials after a 1-minute elution step.
[0168] Example 6
[0169] DNA binding and elution assays
[0170] 1 mg of morpholine functionalized magnetic beads was added to 1 mL of 200 bp DNA solution with various pH and salt concentrations (pH 5.8-pH 8.4; 0-600 mM NaCl). The suspension was mixed for 40 seconds. The particles were collected with a magnetic bar for 1 minute. The supernatant was collected to measure the remaining DNA concentration in the solution and thus calculate the binding percentage. dsDNA system (Promega) was used to quantify DNA concentration. 50 μL Tris buffer (10 mM, pH 9.0) was added to the magnetic particles, and the suspension was vortexed for 1 minute. The particles were collected with a magnetic bar. The elution solution was collected, and the DNA concentration in the elution solution was quantified to calculate the elution percentage.
[0171] Results are shown in Figure 5 and demonstrated that morpholine-functionalized beads can work over a wide range of initial binding pH and NaCl concentrations.
[0172] Example 7
[0173] DNA binding and elution assays
[0174] 1mg morpholine functionalized magnetic beads were added to 1ml total human DNA (100ng, 10ng or 1ng) phosphate buffered saline (PBS) pH 7.0 solution. The suspension was mixed for 60 seconds. The particles were collected with a magnetic bar for 1 minute. The supernatant was removed, 50 μL Tris buffer (10mM, pH 9.0) was added to the magnetic particles, and the suspension was vortexed for 1 minute. The particles were collected with a magnetic bar. The elution solution was collected, and the DNA concentration in the elution solution was quantitatively calculated using a probe-based quantitative real-time PCR (qPCR) to calculate the elution concentration. The β-2-microglobulin probe and primers were used to compare the DNA solution input and elution concentrations.
[0175] Results are shown in Figure 6 Morpholino-functionalized beads are able to concentrate total DNA, and the DNA can subsequently be used in downstream qPCR reactions.
[0176] Example 8
[0177] RNA binding and elution assays
[0178] 1mg morpholine functionalized magnetic beads are added to 1mL total RNA (1000ng, 100ng or 10ng) phosphate buffered saline (PBS) pH 7.0 solution. The total RNA used in this assay is isolated from human embryonic kidney 293 cells (commonly referred to as HEK 293 cells, HEK-293 cells or 293 cells). The suspension is mixed for 60 seconds. The particles are collected with a magnetic bar for 1 minute. The supernatant is removed, 50 μL Tris buffer (10mM, pH 9.0) is added to the magnetic particles, and the suspension is vortexed for 1 minute. The particles are collected with a magnetic bar. The elution solution is collected, and the DNA concentration in the elution solution is quantitatively calculated using a probe-based 1-step quantitative real-time PCR (RT-qPCR). β-2-microglobulin probe and primers are used to compare RNA solution input and elution concentrations.
[0179] Results are shown in Figure 7 Morpholino-functionalized beads can concentrate total RNA, and the RNA can then be used in a downstream 1-step RT-qPCR reaction.
[0180] Example 9
[0181] ccfDNA (cell-free circulating DNA) was isolated from 1 mL of human plasma using a Promega Maxwell instrument. Method 1 is a current Promega stock product (#AS1480). Method 2 uses morpholine functionalized magnetic beads of the present disclosure. Method 2 also includes a low pH salt wash after the binding step. The recovered ccfDNA was measured by qPCR.
[0182] Results are shown in Figure 8 The rapid sample preparation chemistry using the morpholine functionalized beads of the present disclosure in method 2 can rapidly isolate and concentrate ccfDNA with high recovery yields. In all three plasma samples, the rapid sample preparation chemistry using morpholine functionalized beads produced higher yields than the commercial Promega Maxwell ccfDNA kit.
Claims
1. A composition comprising: Solid surface; a linker covalently attached to the solid surface; and The moiety of formula (I) covalently linked to the linker: in: X is selected from O, S, S(O) and S(O)2; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano, nitro, -OR a 、-SR b 、-C(O)OR c 、-C(O)NR d R e 、-OC(O)NR f R g 、-NR h C(O)NR i R j and-NR h C(S)NR i R j , where each R a , R b , R c , R d , R e , R f , R g , R h , R i and R j Independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl and aryl.
2. The composition of claim 1, wherein the solid surface comprises a material selected from the group consisting of silicon dioxide, glass, polymers and metals.
3. The composition of claim 1 or 2, wherein the solid surface comprises a polymer selected from cellulose, cellulose acetate, nitrocellulose, nylon, polyester, polyethylene, polyethersulfone, polyolefin, polyvinylidene fluoride, polyacrylate, polystyrene, or any combination thereof.
4. The composition of any one of claims 1 to 3, wherein the solid surface is in the form of a bead, a resin, a magnetic particle, a membrane, a vial, a plate, a film, a tube, a syringe, a column, a box, a pipette tip, a microfluidic column, or a test tube.
5. The composition of any one of claims 1 to 4, wherein the linker comprises one or more methylene, ether, ester, amide, carbamate, carbonate, urea, thioether, thioester, thioamide, thiocarbamate, thiocarbonate, thiourea, arylene, heteroarylene, or heterocyclylene moieties, or any combination thereof.
6. The composition of any one of claims 1 to 5, wherein the linker comprises one or more -CH2-, -O-, -C(O)O-, -C(O)NH-, -NHC(O)O-, -OC(O)O-, -NHC(O)NH-, -S-, -C(O)S-, -C(S)NH-, -NHC(S)O-, -OC(S)O-, -NHC(S)NH-, arylene, heteroarylene, or heterocyclylene moieties, or any combination thereof.
7. The composition of any one of claims 1 to 5, wherein the linker comprises a moiety selected from:
8. The composition of any one of claims 1 to 5, wherein the linker has the following structure: -(CH2) n1 -Z-(CH2) n2 - wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8, and Z is selected from -NHC(O)NH-, -C(O)NH-, -OC(O)NH-, -OC(O)O-, -NHC(O)S-, -NHC(S)NH-, -O-, -C(O)O- and a bond.
9. The composition of any one of claims 1 to 6 and 8, wherein the linker is selected from:
10. The composition of claim 9, wherein the linker is:
11. The composition of any one of claims 1 to 10, wherein X is O.
12. The composition of any one of claims 1 to 11, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is hydrogen.
13. The composition of any one of claims 1 to 12, wherein the solid surface further comprises one or more additional moieties covalently bound to the surface.
14. The composition of any one of claims 1 to 13, wherein the solid surface further comprises at least one polyethylene glycol (PEG) moiety covalently bound to the surface.
15. A method for isolating nucleic acid from a sample, the method comprising: (a) providing a sample containing nucleic acid; (b) contacting the sample with a composition as described in any one of claims 1 to 14 at a pH of less than about 8.0, wherein the nucleic acid binds to the composition to provide a nucleic acid binding composition; as well as (c) isolating the nucleic acid binding composition from the sample.
16. The method of claim 15, wherein step (b) is performed at a pH of about 2.0 to less than about 8.
0.
17. The method of claim 15, wherein step (b) is performed at a pH of about 6.0 to about 7.
5.
18. The method of any one of claims 15 to 17, wherein step (b) comprises contacting the sample with the composition for about 10 seconds to about 10 minutes.
19. The method of any one of claims 15 to 18, wherein step (b) comprises contacting the sample with the composition for about 1 minute to about 5 minutes.
20. The method of any one of claims 15 to 19, further comprising one or more steps of washing the nucleic acid binding composition after step (c) by contacting the composition with a wash solution having a pH of less than about 8.
0.
21. The method of any one of claims 15 to 20, further comprising the step of contacting the nucleic acid binding composition with an elution solution at a pH of about 8.5 or greater to release the nucleic acids from the composition.
22. The method of claim 21, wherein the elution solution comprises an aqueous buffer.
23. The method of claim 21 or 22, comprising contacting the nucleic acid binding composition with the elution solution at a pH of about 8.5 to about 9.
5.
24. The method of claim 23, comprising contacting the nucleic acid binding composition with the elution solution at a pH of about 8.5 to about 9.
0.
25. The method of any one of claims 22 to 24, comprising contacting the nucleic acid binding composition with the elution solution for about 10 seconds to about 10 minutes.
26. The method of any one of claims 22 to 25, comprising contacting the nucleic acid binding composition with the elution solution for about 1 minute to about 5 minutes.
27. The method of any one of claims 15 to 20, comprising subjecting the nucleic acid binding composition to a polymerase chain reaction.
28. The method of any one of claims 15 to 27, wherein the sample comprises a body fluid.
29. The method of claim 28, wherein the body fluid is selected from the group consisting of blood, saliva, lymph, milk, mucus, urine, sweat, amniotic fluid, cerebrospinal fluid, feces, vaginal secretions, and semen.
30. The method of any one of claims 15 to 27, wherein the sample comprises cultured cells, tissue cells, or cells from a body fluid.
31. The method of claim 30, wherein the sample is a blood sample selected from the group consisting of whole blood, plasma and serum.
32. The method of any one of claims 15 to 27, wherein the sample is an environmental sample selected from soil and water.
33. The method of any one of claims 15 to 27, wherein the sample is a food sample.
34. The method of any one of claims 15 to 27, wherein the sample is a plant.
35. The method of any one of claims 15 to 34, wherein the sample comprises a virus, a bacterium, a fungus, or any combination thereof.
36. The method of claim 35, wherein the sample comprises a fungus selected from the group consisting of yeast and mold.
37. The method of any one of claims 15 to 37, wherein the sample comprises a cell lysate, a cell supernatant, or a purified fraction of cells.
38. The method of any one of claims 15 to 37, wherein the method comprises the step of lysing the sample prior to step (b).
39. The method of any one of claims 15 to 38, wherein the nucleic acid is DNA.
40. The method of claim 39, wherein the DNA is selected from total DNA, mtDNA (mitochondrial DNA), gDNA (genomic DNA), cfDNA (cell-free DNA), ccfDNA (circulating cell-free DNA), cffDNA (cell-free fetal DNA), bacterial DNA, viral DNA, and ctDNA (circulating tumor DNA).
41. The method of any one of claims 15 to 38, wherein the nucleic acid is RNA.
42. The method of claim 41, wherein the RNA is selected from total RNA, miRNA, mRNA, tRNA, rRNA, siRNA, ctRNA (circulating tumor RNA), and viral RNA.
43. The method of any one of claims 15 to 38, wherein the nucleic acid is total nucleic acid from the sample.
44. A compound of formula (IIa): or a salt thereof, wherein: X is selected from O, S, S(O) and S(O)2; L is the connector; Each R a are independently selected from hydroxy, C1-C6 alkoxy and halo; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, cyano, nitro, -OR a 、-SR b 、-C(O)OR c 、-C(O)NR d R e 、-OC(O)NR f R g NR h C(O)NR i R j and-NR h C(S)NR i R j , where each R a , R b , R c , R d , R e , R f , R g , R h , R i and R j Independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl and aryl.
45. The compound or salt thereof of claim 44, wherein X is O.
46. A compound or salt thereof as claimed in claim 44 or 45, wherein each R a It is a C1-C6 alkoxy group.
47. A compound or salt thereof as claimed in any one of claims 44 to 46, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 Each is hydrogen.
48. A compound or salt thereof as described in any one of claims 44 to 47, wherein L comprises one or more methylene, ether, ester, amide, carbamate, carbonate, urea, thioether, thioester, thioamide, thiocarbamate, thiocarbonate, thiourea, arylene, heteroarylene or heterocyclylene moieties or any combination thereof.
49. A compound or salt thereof as described in any one of claims 44 to 48, wherein L comprises one or more -CH2-, -O-, -C(O)O-, -C(O)NH-, -NHC(O)O-, -OC(O)O-, -NHC(O)NH-, -S-, -C(O)S-, -C(S)NH-, -NHC(S)O-, -OC(S)O-, -NHC(S)NH-, arylene, heteroarylene or heterocyclylene moieties or any combination thereof.
50. A compound or salt thereof as described in any one of claims 44 to 47, wherein L comprises a moiety selected from:
51. A compound or salt thereof as described in any one of claims 44 to 47, wherein L has the formula: -(CH2) n1 -Z-(CH2) n2 - wherein n1 and n2 are each independently selected from 1, 2, 3, 4, 5, 6, 7 and 8, and Z is selected from -NHC(O)NH-, -C(O)NH-, -OC(O)NH-, -OC(O)O-, -NHC(O)S-, -NHC(S)NH-, -O-, -C(O)O- and a bond.
52. A compound or salt thereof as described in any one of claims 44 to 48 and 51, wherein L has a structure selected from the following:
53. The compound or salt thereof of claim 52, wherein L has the following structure:
